AstraZeneca plans $3.5bn US research and manufacturing expansion before 2027

AstraZeneca has allocated $3.5billion to expand its US manufacturing and research footprint by the end of 2026.

The funding announcement includes $2bn of new investment for more than 1,000 new, high-skilled jobs in the US, adding to the 17,800 employees currently working across 17 R&D, manufacturing and commercial sites spanning 12 US states.

The multinational pharmaceutical and biotechnology company, which is headquartered at the Cambridge Biomedical Campus, will add new facilities to its US operation including:

- An R&D centre in Kendall Square, Cambridge, Massachusetts
- A next-generation manufacturing facility for biologics in Maryland
- Cell therapy manufacturing capacity on the West and East Coasts
- Specialty manufacturing in Texas

AstraZeneca CEO Pascal Soriot said: “Our multi-billion dollar investment reflects the attractiveness of the business environment, together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the US’ leadership in healthcare innovation.”